Immunotherapy Outlook Toward 2030 – System-Based Therapy & Clinical Trial Trend Dataset Compiled by unexakorea

Dataset Description This dataset provides a structured, research-ready summary of key messages, enabling technology pillars, and clinical trial landscape statistics related to next-generation immunotherapy toward 2030. The dataset is designed to support secondary analysis, evidence mapping, and reproducible reporting on the transition of immunotherapy from a drug-centered paradigm to a system-based therapy model. The dataset includes (1) a curated set of core strategic messages extracted from an immunotherapy outlook manuscript, (2) a taxonomy of system-enabling capabilities such as combination optimization, biomarker-driven patient stratification, monitoring, immune-related adverse event (irAE) management, real-world data (RWD)-driven optimization, and workflow-oriented infrastructure (e.g., “Cell Therapy Patient Journey OS”), and (3) summarized clinical trial landscape counts for CAR-T, CAR-NK, and TIL modalities based on secondary analyses reported in peer-reviewed literature. Scope and Intended Use This dataset does not contain individual-level patient data. All numerical values are derived from cited secondary sources and should be interpreted as literature-based snapshots rather than real-time registry totals. The dataset is intended for research, policy, market analysis, and technology strategy discussions, and can be extended by adding updated registry counts, region-specific breakdowns, or organization-level landscape records.